Cargando…
Quantitative Assessment of PD-L1 as an Analyte in Immunohistochemistry Diagnostic Assays using a Standardized Cell Line Tissue Microarray
Programmed Death 1 Ligand 1 (PD-L1) Immunohistochemistry (IHC) is the key FDA-approved predictive marker to identify responders to anti-PD1 axis drugs. Multiple PD-L1 IHC assays with various antibodies and cut-points have been used in clinical trials across tumor types. Comparative performance chara...
Autores principales: | Martinez-Morilla, Sandra, McGuire, John, Gaule, Patricia, Moore, Lauren, Acs, Balazs, Cougot, Delphine, Gown, Allen M., Yaziji, Hadi, Wang, Wei-Lien, Cartun, Richard W., Hornick, Jason L., Sholl, Lynette M., Qiu, Jingxin, Mino-Kenudson, Mari, Yi, Eunhee S., Beasley, Mary Beth, Merrick, Daniel T., Ambaye, Abiy B., Zhang, Zhong J., Walker, Jill, Rimm, David L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920558/ https://www.ncbi.nlm.nih.gov/pubmed/31409885 http://dx.doi.org/10.1038/s41374-019-0295-9 |
Ejemplares similares
-
Clinical and Molecular Validation of BAP1, MTAP, P53, and Merlin Immunohistochemistry in Diagnosis of Pleural Mesothelioma
por: Chapel, David B., et al.
Publicado: (2022) -
Standardization of PD-L1 immunohistochemistry
por: Martinez-Morilla, Sandra, et al.
Publicado: (2021) -
ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients
por: Uruga, Hironori, et al.
Publicado: (2018) -
Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
por: Mino-Kenudson, Mari
Publicado: (2016) -
Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma
por: Yang, Michelle X., et al.
Publicado: (2018)